Biomedical Innovations

Gurus BioPharm LLC (“Gurus”) is a research company developing innovative drugs. We develop groundbreaking Russian biopharmaceutical innovations from the early stages to commercialization at the global market. 

Respiratory system
GUR-501 Asthma treatment First in class

GUR-501 has a potential to be first drug with new mode of action. Asthma causes acute bronchospasm. ~5% of population suffer from asthma. Funded: $721,000. Supported by

Stage: Preclinical trials
Cardiovascular system
GUR-201 Critical Limb Ischemia treatment (CLI) Best-in-class

GUR-201 is designed to treat CLI caused by diabetes or peripheral artery disease. CLI leads to severe complications up to amputation. 1%-2% of population suffer CLI

Stage: Preclinical trials
Hair growth stimulation
REG-103 Hair growth stimulator

This innovative molecular complex acts on hair follicles stimulating hair growth on a head by increasing blood supply to follicles

Stage: In sales

Gurus BioPharm LLC is a resident of Skolkovo Fund